Volume 24, Number 12—December 2018
CME ACTIVITY - Research
Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1
|Model||HR (95% CI)||p value|
|Intervention arm (receiving individualized texting for adherence to daily TDF/FTC)||1.377 (0.862–2.200)||0.180|
|Baseline some substance use (any)||0.743 (0.426–1.293)||0.293|
|Baseline frequent substance use (any)||0.541 (0.304–0.961)||0.036|
|Intervention arm||0.924 (0.671–1.272)||0.626|
|Baseline some stimulant use||2.690 (1.727–4.190)||<0.001|
|Baseline frequent stimulant use||2.604 (1.665–4.072)||<0.001|
|Positive STI test result at baseline||1.450 (1.031–2.039)||0.033|
*Model 1 assessed the effect of baseline substance use on early study termination. Model 2 assessed the association of stimulant use and incident STIs during the study. FTC, emtricitibine; HR, hazard ratio; MSM, men who have sex with men; STI, sexually transmitted infection; TDF, tenofovir disoproxil fumarate.
1Original data from this study were presented in part at the 2017 Conference on Retroviruses and Opportunistic Infections, February 13–16, 2017, Seattle, Washington, USA; and at the 12th International Conference on HIV Treatment and Prevention Adherence, June 4–6, 2017, Miami, Florida, USA.